drugset / Trial / NCT06455358
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
RandomizedParallel-groupSingle-blindDiagnostic
Summary
The goal of this monocentric, open-label, randomized-controlled, reader-blind clinical study is to assess the safety of the radiolabeled somatostatin receptor ligand, 61Cu-NODAGA-LM3, and its sensitivity in comparison to the standard of care, 68Ga-DOTATOC, for PET/CT imaging in patients with well differentiated bronchopulmonary and gastroenteropancreatic neuroendocrine tumors.
Timeline
- Start
- 2025-02-05
- Primary completion
- 2028-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 61Cu-NODAGA-LM3 | Diagnostic / imaging agent | 20 ug | Intravenous |
| Subject | 61Cu-NODAGA-LM3 | Diagnostic / imaging agent | 40 ug | Intravenous |
| Subject | 61Cu-NODAGA-LM3 | Diagnostic / imaging agent | 150 mbq | Intravenous |
| Subject | 68Ga-DOTATOC | Peptide | — | Intravenous |